Krsnaa Diagnostics FY26 PAT Jumps 31% to ₹1,014 Million; Recommends ₹2 Dividend
Krsnaa Diagnostics reported FY26 consolidated revenue of ₹7,728 million and PAT of ₹1,014 million, up 31%. Diluted EPS was ₹30.88. Operating cash flows grew 64% to ₹1,431 million. The Board recommended a ₹2 per share final dividend.
The announcement details substantial financial growth, record PAT, improved operational efficiency, and a positive outlook with a dividend recommendation, which are material events for investors.
The company reported strong financial results with significant PAT and EPS growth, improved operating cash flows, and a recommended dividend. The expansion of its retail vertical was also highlighted as a key growth driver.
Krsnaa Diagnostics Limited announced its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company reported consolidated revenue of ₹7,728 million and a Profit After Tax (PAT) growth of 31% to ₹1,014 million, marking the highest PAT since its listing.
This PAT includes a fair valuation gain of ₹221.75 million from the investment in Apulki Healthcare Private Limited. The Diluted Earnings Per Share (EPS) also saw a 31% improvement, reaching ₹30.88. Operating cash flows strengthened significantly by approximately 64% year-on-year, increasing from ₹873 million in FY2025 to ₹1,431 million in FY2026, attributed to structural improvements in collections and working capital management.
The Board of Directors has recommended a final dividend of ₹2 per share of face value ₹5. The company highlighted its growth roadmap, focusing on long-term Public-Private Partnership (PPP) contracts, a scaling Business-to-Consumer (B2C) vertical, and expansion into tertiary care through Apulki Healthcare.
Mr. Mitesh Dave, Group CEO, noted FY2026 as a pivotal point, with the retail diagnostics vertical, Krsnaa Retail Private Limited, emerging as a significant growth engine. Krsnaa Retail achieved an 8-fold increase in revenue and a 7-fold surge in touchpoints, expanding to 3,500 locations across 5 states within twelve months.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.